The Motley Fool fool.com 31 Jul, 2022 18:30 am

Where Will CRISPR Therapeutics Be in 1 Year?

Where Will CRISPR Therapeutics Be in 1 Year?
The next 12 months could look very different from the past year for this biotech company.

The past year has been challenging for gene-editing specialist CRISPR Therapeutics (CRSP -1.Clinical-stage biotechs like CRISPR Therapeutics that aren't consistently profitable were hit especially hard.What will the next 12 months have in store for CRISPR Therapeutics?CRISPR Therapeutics' leading pipeline candidate is exa-cel (formally known as CTX001), a potential gene-editing therapy for two rare blood disorders called transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD).

CRISPR Therapeutics is collaborating with biotech giant Vertex Pharmaceuticals on these programs.Once CRISPR Therapeutics officially announces these submissions, expect its stock to jump on the news.

Read full story at fool.com